One patient with t(1;11)(p32;q23) was reclassified as having AML with KMT2A rearrangement (AML-KMT2A) using the 2022 WHO criteria and AML with other KMT2A rearrangements using the ICC. The gene discussed is KMT2A; the disease is acute myeloid leukemia.